Mortality Risk Associated with Long-acting Injectable Antipsychotics: A Systematic Review and Meta-analyses of Randomized Controlled Trials

Schizophrenia Bulletin

Volumn 42, Issue 6, 2016, Pages 1438-1445

  Kishi, Taro ^a   Matsunaga, Shinji ^a   Iwata, Nakao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

long acting injectable antipsychotics; meta analysis; mortality; schizophrenia; systematic review

Indexed keywords

ARIPIPRAZOLE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LONG ACTING DRUG; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PIMOZIDE; RISPERIDONE; ZUCLOPENTHIXOL; DELAYED RELEASE FORMULATION;

ARTICLE; DISEASE EXACERBATION; DRUG DOSAGE FORM COMPARISON; HUMAN; INCIDENCE; META ANALYSIS; MORTALITY RISK; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SUICIDE; SYSTEMATIC REVIEW; TREATMENT DURATION; ADVERSE EFFECTS; DELAYED RELEASE FORMULATION; MORTALITY;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84994403327     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbw043     Document Type: Article

References (33)

1. Nielsen RE, Uggerby AS, Jensen SO, McGrath JJ. Increasing mortality gap for patients diagnosed with schizophrenia over the last three decades-a Danish nationwide study from 1980 to 2010. Schizophr Res. 2013;146:22-27.
2. Hoang U, Stewart R, Goldacre MJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. BMJ. 2011;343:d5422.
3. Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 2015;72:1172-1181.
4. Reininghaus U, Dutta R, Dazzan P, et al. Mortality in schizophrenia and other psychoses: a 10-year follow-up of the ÆSOP first-episode cohort. Schizophr Bull. 2015;41:664-673.
5. DE Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10:52-77.
6. Osby U, Westman J, Hallgren J, Gissler M. Mortality trends in cardiovascular causes in schizophrenia, bipolar and unipolar mood disorder in Sweden 1987-2010 [published online ahead of print January 8, 2016]. Eur J Public Health.
7. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72:334-341.
8. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123-1131.
9. Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10:425-448.
10. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8:114-126.
11. Henderson DC, Vincenzi B, Andrea NV, Ulloa M, Copeland PM. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry. 2015;2:452-464.
12. Popovic D, Benabarre A, Crespo JM, et al. Risk factors for suicide in schizophrenia: systematic review and clinical recommendations. Acta Psychiatr Scand. 2014;130:418-426.
13. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2012;5:CD008016.
14. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year followup of mortality in patients with schizophrenia: a populationbased cohort study (FIN11 study). Lancet. 2009;374:620-627.
15. Tiihonen J, Wahlbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333:224.
16. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168:603-609.
17. Tiihonen J, Mittendorfer-Rutz E, Torniainen M, Alexanderson K, Tanskanen A. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study [published online ahead of print December 7, 2015]. Am J Psychiatry.
18. Spanarello S, La Ferla T. The pharmacokinetics of longacting antipsychotic medications. Curr Clin Pharmacol. 2014;9:310-317.
19. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirrorimage studies. J Clin Psychiatry. 2013;74:957-965.
20. Fusar-Poli P, Kempton MJ, Rosenheck RA. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol. 2013;28:57-66.
21. Fujii Y. [What Lessons Should We Learn from the Death of Patients on Xeplion?]. Seishin Shinkeigaku Zasshi. 2015;117:132-145.
22. Button KS, Ioannidis JP, Mokrysz C, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013;14:365-376.
23. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. BMJ. 2009;339:b2535.
24. De Risio A, Lang AP. History and therapeutic rationale of long acting antipsychotics. Curr Clin Pharmacol. 2014;9:39-52.
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
26. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010;67:255-262.
27. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64:663-667.
28. Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic D. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry. 2003;64:2-97, quiz 98-100.
29. McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet. 2000;356: 1228-1231.
30. Potapov A, Eduard T, Sergey M. Response, remission and relapse during the long-term treatment of schizophrenia patients with long-acting injectable risperidone versus olanzapine. Int J Neuropsychop. 2008;11:158-158.
31. Haddad PM, Kishimoto T, Correll CU, Kane JM. Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance. Curr Opin Psychiatry. 2015;28:216-221.
32. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40:192-213.
33. Masand PS, Gupta S. Long-acting injectable antipsychotics in the elderly: guidelines for effective use. Drugs Aging. 2003;20:1099-1110.